Published in The American, October 1, 2008American free-marketers often criticize Europe for its misguided regulation of the drug industry, rightly attributing the continent’s paucity of pharmaceutical innovation to its penchant for price controls. But when it comes to promoting innovation and investment in today’s most revolutionary medicines, biologic drugs, the Europeans have … [Read more...] about Regulatory Lessons from Europe